A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Cannot have received: small molecule anti-cancer drug

Small molecule anti-cancer drugs within 5 half-lives or 2 days (whichever is longer, not to exceed 14 days)

Cannot have received: systemic chemotherapy

Systemic chemotherapy within 14 days

Cannot have received: radiation therapy

Radiation therapy within 14 days

Cannot have received: biologic therapy

Biologics (Antibodies) treatment within 28 days

Cannot have received: radioimmunoconjugate or toxin conjugate

Radioimmunoconjugates or toxin conjugates within 12 weeks

Cannot have received: CAR-T cell therapy

Prior Chimeric antigen receptor (CAR) T cell therapy (and prior use of immunoglobulin replacement therapy to treat associated adverse events) within 3 months. For patients with DLBCL, no prior CAR- T therapy is allowed.

Cannot have received: autologous or allogenic stem cell transplant

Autologous or allogenic stem cell transplant within 100 days and must not have ongoing graft-versus-host disease (GVHD) and no ongoing therapy to treat GVHD